6533b873fe1ef96bd12d565c

RESEARCH PRODUCT

Salivary and serum levels of substance p, neurokinin A and calcitonin gene related peptide in burning mouth syndrome

Iva AlajbegVanja-vucicevic BorasVlaho BrailoMaja LukacNeil-william SavageJosip Lukač

subject

Malemedicine.medical_specialtySalivaCalcitonin Gene-Related PeptideNeurokinin ANeuropeptideSubstance PBurning Mouth SyndromeCalcitonin gene-related peptideSubstance Pchemistry.chemical_compoundInternal medicinemedicineHumansSalivaGeneral DentistryAgedbusiness.industryDopaminergicBurning mouth syndromeMiddle Agedrespiratory system:CIENCIAS MÉDICAS [UNESCO]stomatognathic diseasesEndocrinologyOtorhinolaryngologychemistryCalcitoninUNESCO::CIENCIAS MÉDICASSubstance P ; neurokinin A ; calcitonin gene-related peptide ; burning mouth syndromeSurgeryFemaleNeurokinin Amedicine.symptombusiness

description

Background: Burning mouth syndrome (BMS) is an enigmatic condition with the etiopathogenesis remaining largely obscure. However, a neuropathic basis for BMS continues to be an area of active clinical and research interest. Aim: It is becoming increasingly evident that certain oral disorders may be modulated by imbalances in certain neuropeptides such as substance P (SP), neurokinin A (NKA) and calcitonin gene-related peptide (CGRP) therefore we measured SP, NKA and CGRP in the saliva and sera of BMS patients as well as controls. Subjects and Methods: Salivary and serum SP, NKA and CGRP were determined in the 26 female patients with burning mouth syndrome (age range 51-78, mean 65.69 yrs), and in the 22 female controls (age range 24-82, mean 49.72 yrs). Serum and salivary SP, NKA, CGRP levels were determined by commercial competitive enzyme immunoassay kits. Statistical analysis was performed by use of descriptive statistics and analysis of variance. Results and Conclusions: No significant differences in salivary SP, NKA and CGRP as well as serum SP and CGRP between BMS patients and controls could be found. However, significantly decreased serum neurokinin A (p<0.05) in BMS patients may reflect an inefficient dopaminergic system.

10.4317/medoral.15.e427http://hdl.handle.net/10550/60335